Single-layer PRF membrane application

PreclinicalBiologic

AAl-Mustansiriyah University

Single-layer PRF membrane application is one of 7 biologic programs targeting ISS. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ISSCompleted

ISSPreclinical

Completed

Competition

Competitive Landscape

8 competitors in ISS

#DrugCompanyPhaseTrials

Ginaton

PPeking University People's Hospital

Phase 3

1 2

Myrbetriq

Astellas

Phase 1

3 3

Methylprednisolone Hemisuccinate

BBBB-Therapeutics B.V.

Phase 3

1 4

Acellular Adipose Tissue (AAT)

JJohns Hopkins University

Phase 2

2 5

Reboxetine

UUniversity of Zurich

Preclinical

1 6

Psilocybine

UUniversity of Zurich

Preclinical

1 7

Single-layer PRF membrane application

AAl-Mustansiriyah University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

ISS1 trial

The Effect of Platelet Rich Fibrin Layers on Peri-implant Tissue Phenotype

Completed·—·N/A·NCT07033351·31 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Single-layer PRF membrane application. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Single-layer PRF membrane application compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Single-layer PRF membrane application. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Al-Mustansiriyah University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: AAl-Mustansiriyah University

Single-layer PRF membrane application

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

ISS1 trial

References

Drug Info

Quick Facts

Related News